Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Oncology

Journal Scan / Research · November 28, 2019

Capecitabine and Temozolomide vs FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer

Clinical Cancer Research

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Clinical Cancer Research
Capecitabine and Temozolomide Versus FOLFIRI in RAS Mutated, MGMT Methylated Metastatic Colorectal Cancer
Clin. Cancer Res 2019 Nov 18;[EPub Ahead of Print], F Pietrantonio, R Lobefaro, M Antista, S Lonardi, A Raimondi, F Morano, S Mosconi, L Rimassa, S Murgioni, A Sartore-Bianchi, G Tomasello, R Longarini, G Farina, F Petrelli, S Gori, G Randon, S Corallo, F Pagani, V Guarini, F Palermo, A Martinetti, M Macagno, L Barault, F Perrone, E Tamborini, M Milione, F Di Nicolantonio, M Di Maio, G Fucà, M Di Bartolomeo, F de Braud

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated